TCGA-MP-A4SY-01A-21R-A24X-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 61
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.490
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.420
- PROTEIN_SECRETION+0.260
- HEDGEHOG_SIGNALING+0.250
- TGF_BETA_SIGNALING+0.210
- MYOGENESIS+0.190
- KRAS_SIGNALING_UP+0.180
- APOPTOSIS+0.150
- UV_RESPONSE_DN+0.120
- COAGULATION+0.110
Top 10 suppressed
- E2F_TARGETS-0.460
- G2M_CHECKPOINT-0.450
- OXIDATIVE_PHOSPHORYLATION-0.390
- SPERMATOGENESIS-0.340
- ALLOGRAFT_REJECTION-0.310
- KRAS_SIGNALING_DN-0.250
- APICAL_SURFACE-0.240
- CHOLESTEROL_HOMEOSTASIS-0.200
- DNA_REPAIR-0.200
- FATTY_ACID_METABOLISM-0.190
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 8d532c55-71b5-4992-9aba-7480d7c390ce | — | — | 0.780 |
| 2 | TCGA-E9-A1NH-01A-11R-A14D-07 | — | A | 0.770 |
| 3 | TCGA-HD-7831-01A-11R-2132-07 | — | — | 0.770 |
| 4 | 20679021-a108-4728-ab9a-fa3ca2fed0d0 | — | — | 0.762 |
| 5 | df16e2f1-59a7-444d-9eab-c8d3b23b080d | — | — | 0.762 |
| 6 | 5af21474-88f9-4885-82d2-9c84b2ded99a | — | — | 0.757 |
| 7 | 7900174d-af00-444f-a5b2-226a45f7e76a | — | — | 0.756 |
| 8 | X9d79253b.8c45.4bde.a42d.c399fb107400 | — | cohortMD2 | 0.755 |
| 9 | TCGA-FD-A5BZ-01A-11R-A28M-07 | — | — | 0.754 |
| 10 | 20020009.LumA | — | A | 0.753 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.490 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.420 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.260 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.250 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.210 | Inavolisib | — uncovered |
| MYOGENESIS | 0.190 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.180 | Inavolisib | — uncovered |
| APOPTOSIS | 0.150 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.120 | Inavolisib | — uncovered |
| COAGULATION | 0.110 | Binimetinib | — uncovered |
| P53_PATHWAY | 0.110 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.100 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.100 | Inavolisib | — uncovered |
| HYPOXIA | 0.100 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.100 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.060 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.060 | Inavolisib | — uncovered |